Arcus Biosciences (RCUS) Accounts Payables (2017 - 2026)

Arcus Biosciences has reported Accounts Payables for 10 years, with the latest figure at $39.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 77.27% year-over-year to $39.0 million; the trailing twelve-month figure through Mar 2026 stood at $39.0 million (up 77.27% YoY), and the FY2025 full-year result was $42.0 million, up 133.33% from the prior year.
• Accounts Payables for Q1 2026 stood at $39.0 million, down from $42.0 million in the prior quarter.
• The five-year high for Accounts Payables was $42.0 million in Q3 2025, with the low at $10.5 million in Q3 2022.
• Average Accounts Payables over 5 years is $22.4 million, with a median of $18.1 million recorded in 2022.
• Year-over-year, Accounts Payables plunged 45.41% in 2023 and surged 223.08% in 2025.
• Tracing RCUS's Accounts Payables over 5 years: stood at $20.0 million in 2022, then decreased by 15.0% to $17.0 million in 2023, then grew by 5.88% to $18.0 million in 2024, then surged by 133.33% to $42.0 million in 2025, then slipped by 7.14% to $39.0 million in 2026.
• The last three Accounts Payables figures came in at $39.0 million (Q1 2026), $42.0 million (Q4 2025), and $42.0 million (Q3 2025), per Business Quant data.

Peer Comparison